Skip to main navigation
Kalaris Therapeutics
  • About Us
  • Our Science
  • Leadership Team
  • Contact
  • Investors & Press

Event Details

  • Overview
  • Press Releases
  • Events & Presentations
  • SEC Filings & Tax Forms
  • Stock Information
  • Analyst Coverage
  • Corporate Governance
  • Email Alerts

Investor Contacts

ir@kalaristx.com



Media Contacts

media@kalaristx.com

Phase 1a Data for TH103 in Treatment-Naïve Neovascular AMD Call

Dec 17, 2025 4:30 PM EST

Listen to webcast

Supporting Materials

TH103 Phase 1a Data Presentation 5.4 MB
© Kalaris Therapeutics 2026. All rights reserved.